These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30359543)

  • 1. Montelukast enhances cytocidal effects of carfilzomib in multiple myeloma by inhibiting mTOR pathway.
    Tong J; Yu Q; Xu W; Yu W; Wu C; Wu Y; Yan H
    Cancer Biol Ther; 2019; 20(3):381-390. PubMed ID: 30359543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway.
    Xiang RF; Wang Y; Zhang N; Xu WB; Cao Y; Tong J; Li JM; Wu YL; Yan H
    Cell Death Dis; 2017 May; 8(5):e2776. PubMed ID: 28492559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma.
    Ponder KG; Matulis SM; Hitosugi S; Gupta VA; Sharp C; Burrows F; Nooka AK; Kaufman JL; Lonial S; Boise LH
    Cancer Biol Ther; 2016 Jul; 17(7):769-77. PubMed ID: 27246906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
    Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
    Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo.
    Ashley JD; Stefanick JF; Schroeder VA; Suckow MA; Alves NJ; Suzuki R; Kikuchi S; Hideshima T; Anderson KC; Kiziltepe T; Bilgicer B
    J Control Release; 2014 Dec; 196():113-21. PubMed ID: 25312543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of the role of carfilzomib in the treatment of multiple myeloma.
    Ziogas DC; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Pharmacother; 2017 Dec; 18(17):1883-1897. PubMed ID: 29134824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological profile and clinical effects of montelukast sodium (Singulair chewable tablet), an antiasthmatic agent].
    Suzuki J; Nishikibe M
    Nihon Yakurigaku Zasshi; 2002 Nov; 120(5):343-52. PubMed ID: 12491810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute suppression of translation by hyperthermia enhances anti-myeloma activity of carfilzomib.
    Maruhashi T; Miki H; Sogabe K; Oda A; Sumitani R; Oura M; Takahashi M; Harada T; Fujii S; Nakamura S; Kurahashi K; Endo I; Abe M
    Int J Hematol; 2024 Mar; 119(3):291-302. PubMed ID: 38252236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Montelukast.
    Markham A; Faulds D
    Drugs; 1998 Aug; 56(2):251-6; discussion 257. PubMed ID: 9711449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells.
    Baranowska K; Misund K; Starheim KK; Holien T; Johansson I; Darvekar S; Buene G; Waage A; Bjørkøy G; Sundan A
    Oncotarget; 2016 Oct; 7(43):70845-70856. PubMed ID: 27683126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
    Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
    Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Montelukast--place in therapy.
    Vora AC
    J Assoc Physicians India; 2014 Mar; 62(3 Suppl):46-50. PubMed ID: 25327061
    [No Abstract]   [Full Text] [Related]  

  • 14. Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation.
    Okabe S; Tanaka Y; Tauchi T; Ohyashiki K
    Ann Hematol; 2019 Mar; 98(3):723-733. PubMed ID: 30430191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carfilzomib for the treatment of multiple myeloma.
    Lue J; Goel S; Mazumder A
    Drugs Today (Barc); 2013 Mar; 49(3):171-9. PubMed ID: 23527321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib.
    Shen X; Wu C; Lei M; Yan Q; Zhang H; Zhang L; Wang X; Yang Y; Li J; Zhu Y; Chen L
    Cell Death Dis; 2021 Apr; 12(5):429. PubMed ID: 33931582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Montelukast. No current use for asthma.
    Can Fam Physician; 2000 Jan; 46():86-99. PubMed ID: 10660791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Successful and effective: Montelukast in clinical practice].
    Internist (Berl); 1999 Dec; 40(12 Suppl Montelukas):1-4. PubMed ID: 10635479
    [No Abstract]   [Full Text] [Related]  

  • 19. Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor.
    Rosebeck S; Alonge MM; Kandarpa M; Mayampurath A; Volchenboum SL; Jasielec J; Dytfeld D; Maxwell SP; Kraftson SJ; McCauley D; Shacham S; Kauffman M; Jakubowiak AJ
    Mol Cancer Ther; 2016 Jan; 15(1):60-71. PubMed ID: 26637366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.
    Stewart AK
    Future Oncol; 2015; 11(15):2121-36. PubMed ID: 26125319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.